Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML

Abstract: The ETAL-1 trial demonstrated that upfront allogeneic hematopoietic stem cell transplant (HSCT) improved disease-free survival, but not overall survival, when compared with consolidation chemotherapy followed by “delayed” HSCT on relapse in patients with intermediate-risk acute myeloid leu...

Description complète

Détails bibliographiques

Auteurs principaux:	Abdulrahman Alhajahjeh, Kishan K. Patel, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Stuart Seropian, Lohith Gowda, Scott F. Huntington, Maximilian Stahl, Amer M. Zeidan, George Goshua, Jan Philipp Bewersdorf
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2025-10-01
Collection:	Blood Advances
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2473952925004446
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!